Liposomes and nanotechnology in drug development: focus on ocular targets

Miki Honda,1 Tomohiro Asai,2 Naoto Oku,2 Yoshihiko Araki,3 Minoru Tanaka,1 Nobuyuki Ebihara11Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan; 2Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; 3Institute fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fc9c2b8aa79a478eb7a7deaf00735327
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc9c2b8aa79a478eb7a7deaf00735327
record_format	dspace
spelling	oai:doaj.org-article:fc9c2b8aa79a478eb7a7deaf007353272021-12-02T02:11:17ZLiposomes and nanotechnology in drug development: focus on ocular targets1176-91141178-2013https://doaj.org/article/fc9c2b8aa79a478eb7a7deaf007353272013-02-01T00:00:00Zhttp://www.dovepress.com/liposomes-and-nanotechnology-in-drug-development-focus-on-ocular-targe-a12210https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Miki Honda,1 Tomohiro Asai,2 Naoto Oku,2 Yoshihiko Araki,3 Minoru Tanaka,1 Nobuyuki Ebihara11Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan; 2Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; 3Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, JapanAbstract: Poor drug delivery to lesions in patients&#39; eyes is a major obstacle to the treatment of ocular diseases. The accessibility of these areas to drugs is highly restricted by the presence of barriers, including the corneal barrier, aqueous barrier, and the inner and outer blood&ndash;retinal barriers. In particular, the posterior segment is difficult to reach for drugs because of its structural peculiarities. This review discusses various barriers to drug delivery and provides comprehensive information for designing nanoparticle-mediated drug delivery systems for the treatment of ocular diseases. Nanoparticles can be designed to improve penetration, controlled release, and drug targeting. As highlighted in this review, the therapeutic efficacy of drugs in ocular diseases has been reported to be enhanced by the use of nanoparticles such as liposomes, micro/nanospheres, microemulsions, and dendrimers. Our recent data show that intravitreal injection of targeted liposomes encapsulating an angiogenesis inhibitor caused significantly greater suppression of choroidal neovascularization than did the injection of free drug. Recent progress in ocular drug delivery systems research has provided new insights into drug development, and the use of nanoparticles for drug delivery is thus a promising approach for advanced therapy of ocular diseases.Keywords: intravitreal injection, drug delivery system, age-related macular degeneration, APRPG-modified PEGylated liposome, DDSHonda MAsai TOku NAraki YTanaka MEbihara NDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 495-504 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Honda M Asai T Oku N Araki Y Tanaka M Ebihara N Liposomes and nanotechnology in drug development: focus on ocular targets
description	Miki Honda,1 Tomohiro Asai,2 Naoto Oku,2 Yoshihiko Araki,3 Minoru Tanaka,1 Nobuyuki Ebihara11Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan; 2Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; 3Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, JapanAbstract: Poor drug delivery to lesions in patients&#39; eyes is a major obstacle to the treatment of ocular diseases. The accessibility of these areas to drugs is highly restricted by the presence of barriers, including the corneal barrier, aqueous barrier, and the inner and outer blood&ndash;retinal barriers. In particular, the posterior segment is difficult to reach for drugs because of its structural peculiarities. This review discusses various barriers to drug delivery and provides comprehensive information for designing nanoparticle-mediated drug delivery systems for the treatment of ocular diseases. Nanoparticles can be designed to improve penetration, controlled release, and drug targeting. As highlighted in this review, the therapeutic efficacy of drugs in ocular diseases has been reported to be enhanced by the use of nanoparticles such as liposomes, micro/nanospheres, microemulsions, and dendrimers. Our recent data show that intravitreal injection of targeted liposomes encapsulating an angiogenesis inhibitor caused significantly greater suppression of choroidal neovascularization than did the injection of free drug. Recent progress in ocular drug delivery systems research has provided new insights into drug development, and the use of nanoparticles for drug delivery is thus a promising approach for advanced therapy of ocular diseases.Keywords: intravitreal injection, drug delivery system, age-related macular degeneration, APRPG-modified PEGylated liposome, DDS
format	article
author	Honda M Asai T Oku N Araki Y Tanaka M Ebihara N
author_facet	Honda M Asai T Oku N Araki Y Tanaka M Ebihara N
author_sort	Honda M
title	Liposomes and nanotechnology in drug development: focus on ocular targets
title_short	Liposomes and nanotechnology in drug development: focus on ocular targets
title_full	Liposomes and nanotechnology in drug development: focus on ocular targets
title_fullStr	Liposomes and nanotechnology in drug development: focus on ocular targets
title_full_unstemmed	Liposomes and nanotechnology in drug development: focus on ocular targets
title_sort	liposomes and nanotechnology in drug development: focus on ocular targets
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/fc9c2b8aa79a478eb7a7deaf00735327
work_keys_str_mv	AT hondam liposomesandnanotechnologyindrugdevelopmentfocusonoculartargets AT asait liposomesandnanotechnologyindrugdevelopmentfocusonoculartargets AT okun liposomesandnanotechnologyindrugdevelopmentfocusonoculartargets AT arakiy liposomesandnanotechnologyindrugdevelopmentfocusonoculartargets AT tanakam liposomesandnanotechnologyindrugdevelopmentfocusonoculartargets AT ebiharan liposomesandnanotechnologyindrugdevelopmentfocusonoculartargets
_version_	1718402691248422912

Liposomes and nanotechnology in drug development: focus on ocular targets

Ejemplares similares